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ABSTRACT
Objectives To explore UK clinicians’ beliefs and 
behaviours around recommending e- cigarettes as a 
smoking cessation aid for patients with cancer.
Design Cross- sectional online survey.
Setting England, Wales, Scotland and Northern Ireland.
Participants Clinicians involved in the care of patients 
with cancer.
Primary and secondary outcomes Behavioural Change 
Wheel capability, opportunity and motivation to perform 
a behaviour, knowledge, beliefs, current practice around 
e- cigarettes and other smoking cessation practices.
Method Clinicians (n=506) completed an online survey 
to assess beliefs and behaviours around e- cigarettes and 
other smoking cessation practices for patients with cancer. 
Behavioural factors associated with recommending e- 
cigarettes in practice were assessed.
Results 29% of clinicians would not recommend e- 
cigarettes to patients with cancer who continue to smoke. 
Factors associated with recommendation include smoking 
cessation knowledge (OR 1.56, 95% CI 1.01 to 2.44) and 
e- cigarette knowledge (OR 1.64, 95% CI 1.06 to 2.55), 
engagement with patients regarding smoking cessation 
(OR 2.12, 95% CI 1.12 to 4.03), belief in the effectiveness 
of e- cigarettes (OR 2.36 95% CI 1.61 to 3.47) and belief 
in sufficient evidence on e- cigarettes (OR 2.08 95% CI 
1.10 to 4.00) and how comfortable they felt discussing 
e- cigarettes with patients (OR 1.57 95% CI 1.04 to 2.36).
Conclusion Many clinicians providing cancer care to 
patients who smoke do not recommend e- cigarettes as 
a smoking cessation aid and were unaware of national 
guidance supporting recommendation of e- cigarettes as a 
smoking cessation aid.
BACKGROUND
Smoking is a well- established risk factor for 
many common cancers.1–3 The adverse effects 
of smoking continue after a cancer diag-
nosis, increasing the risk of treatment- related 
complications, recurrence, the development 
of a second primary cancer and mortality 
from both cancer- related and non- cancer- 
related causes.4–11 Despite the increased risk 
of complications of cancer treatment, recur-
rence and death, many patients with smoking- 
related cancers continue smoking following 
diagnosis12–15 having tried and failed to stop 
smoking. Effective aids for cessation are 
available, but support to quit is not routinely 
offered as part of cancer care.16 17 One study 
found that 39% (n=1129) of patients with 
lung cancer, 37% (n=281) upper aerodiges-
tive tract cancer patients and 49% (n=850) 
of patients with bladder cancer continued to 
smoke 1 year after diagnosis, figures that were 
likely to be higher as a third of the potential 
participants’ smoking status was unknown.18 
To enhance the length and health- related 
quality of their lives, efforts are needed to 
support cancer patients to stop smoking 
cigarettes.
In recent years, e- cigarettes have grown in 
popularity as a cessation aid among smokers 
Strengths and limitations of this study
 ► This study reports an online survey with a wide- 
range of clinicians to assess their beliefs and current 
practices around e- cigarettes as a smoking cessa-
tion aid for cancer patients.
 ► The survey used the capability, opportunity and mo-
tivation (COM- B) behavioural model to understand 
the factors that influence clinicians to recommend 
or not recommend e- cigarettes.
 ► Quota sampling enabled representation across rele-
vant clinical roles in primary and secondary care and 
across geographical areas in the UK.
 ► The sample is limited to UK clinicians where pub-
lic health policy supports use of e- cigarettes as a 
smoking cessation aid for risk reduction compared 
to tobacco cigarette smoking.
 ► The sampling was not random and so participation 
could have been affected by whether clinicians were 
interested in the topic, although paying clinicians to 
complete the study aimed to mitigate this.
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worldwide, but the e- cigarette regulatory environment in 
each country varies considerably due to policy- makers’ 
reactions to a rapidly developing evidence base.19 20 
Often this is influenced by strategic positions on tobacco 
control, for example, harm prevention versus harm 
reduction,21 and whether e- cigarettes are classified as a 
tobacco, medicinal or consumer product.19 The main 
debates focus on trying to achieve a balance between the 
risks and potential of e- cigarettes.21
Support for the use of e- cigarettes for smoking cessa-
tion is endorsed by several health- related organisations 
in the UK including Public Health England,22 Cancer 
Research UK,23 the National Health Service (NHS)24 
and the National Centre for Smoking Cessation and 
Training.25 Public Health Scotland,26 Public Health 
Wales,27 the British Medical Association,28 the Royal 
College of General Practitioners29 and the Royal College 
of Physicians30 also acknowledge that e- cigarettes are 
considered less harmful than smoking tobacco cigarettes 
or that some people may find using e- cigarettes useful for 
stopping or reducing smoking.
In the UK and other European countries, the manufac-
ture, presentation and sales of e- cigarettes are regulated by 
the Tobacco Products Directive (2014/40/EU).31 32 The 
regulation prohibits sales of e- cigarettes to people under 
18 years, most forms of advertising and places restrictions 
on the type and quality of ingredients. In France, there 
are further restrictions on the use of e- cigarettes in public 
places.33 The regulatory environment differs substantially 
in other parts of the world.
In the USA, for instance, the Centres for Disease Control 
and Prevention advice is not unlike many UK public health 
bodies in stating that ‘if (adults) choose to use e- cigarettes 
as an alternative to cigarettes, they should completely 
switch from cigarettes to e- cigarettes and not partake in an 
extended period of dual use of both products that delays 
quitting smoking completely’.34 The WHO position is that 
there is insufficient evidence concerning comparisons 
with combustible cigarettes or efficacy for smoking cessa-
tion, and that the use of e- cigarettes is harmful,35 although 
In October 2018, 72 experts with no connections to the 
tobacco industry wrote to the WHO Director- General to 
argue that WHO should embrace innovation and more 
actively include tobacco harm reduction in its strategy to 
tackle the burden of smoking- related disease.
While the need for further evidence around impacts of 
e- cigarettes on cessation and long- term harms is widely 
acknowledged, many health- related organisations also 
recognise that e- cigarettes may have a potential role 
in smoking cessation and could help people that may 
otherwise continue to smoke. A risk reduction policy to 
encourage smoking cessation is particularly important 
in people who have been diagnosed with cancer who 
continue smoking and therefore increase their risk of 
recurrence, other comorbidities and premature death as 
a result.4–11
In the UK, e- cigarettes have swiftly become the most 
popular smoking cessation product for smokers.36 37 
There are 3.6 million e- cigarettes users in the UK, of which 
only 0.8% have never smoked.37 E- cigarettes are used 
in 30% of quit attempts with currently around 20% of 
smokers and 30% of recent ex- smokers using them.38 
Evidence shows that e- cigarettes help smokers to stop 
smoking long term39–41 and a recent study suggests that 
e- cigarettes are more effective for smoking cessation than 
nicotine- replacement therapy, when both products are 
accompanied by behavioural support.42 However, quali-
tative evidence implies that clinicians may be uncertain 
about the use of e- cigarettes as a cessation aid, with some 
expressing hostility and reporting practices that are not 
consonant with the evidence.43
The aims of this study were to understand clinicians’ 
beliefs and behaviours related to e- cigarettes for patients 
with cancer who continue to smoke, and to understand 
the behavioural factors that may promote or inhibit 
recommending e- cigarettes.
METHODS
Design
The study was a cross- sectional online survey of clinician’s 
knowledge, beliefs and current practice of smoking cessa-
tion and e- cigarettes. The survey was sent to clinicians 
involved in the adult cancer care pathway, working in 
primary and secondary care.
Survey development
The survey was developed using methods suggested by 
Bowling.44 The questions drew on (1) a literature review 
to identify evidence of clinicians’ knowledge, attitudes, 
behaviours and current practice with respect to smoking 
cessation interventions, including e- cigarettes, in patients 
with cancer; (2) expert opinion; (3) drawing on Behaviour 
Change Wheel (BCW).45 46 Development also drew on 
previous survey questions exploring attitudes to e- ciga-
rettes.47–49 The face validity of the survey was evaluated 
with five general practitioners (GPs) and five cancer clini-
cians to evaluate whether the survey was appropriate and 
the questions were understood. This resulted in minor 
modification of wording of some questions.
The final questionnaire was structured according to 
the COM- B behaviour model based on Michie’s BCW for 
development of interventions.45 46 This model proposes 
that people need capability (C), opportunity (O) and 
motivation (M) to perform a behaviour (B) and was devel-
oped to guide understanding of behaviour in context and 
develop behavioural targets. The model proposes that for 
someone to engage in a particular behaviour at a given 
moment they must be physically able and have the psycho-
logical ability and have the social and physical opportu-
nity to enact the behaviour and, in addition, want or need 
to enact the behaviour more than any other competing 
behaviours at that moment. This inclusive definition of 
motivation covers basic drives and automatic processes 
such as habit and impulses as well as reflective processes 
including intention and choice. If a desired behaviour is 
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not occurring (or an undesirable behaviour occurring) 
then an analysis of the determinants of the behaviour will 
help to define what needs to shift in order for the desired 
behaviour to occur (or the unwanted behaviour to cease).
The questionnaire included items relating to psycho-
logical capability (knowledge of smoking status of 
patients, knowledge and skills about smoking cessation 
in general, knowledge and skills about of e- cigarettes); 
physical opportunity (time constraints talking to patients 
about e- cigarettes, physical constraints due to policy); 
social opportunity (relationship with patient and how 
this impacts on smoking cessation advice given, social 
norms, for example, most my colleagues support use 
of e- cigarettes, most my colleagues feel uncomfortable 
recommending e- cigarettes, clinicians should discourage 
smoking); reflective motivation (motivation to engage in 
smoking cessation with cancer patients, beliefs about how 
effective e- cigarettes are for patients with cancer, beliefs 
about the clinician’s role, beliefs about the evidence base 
around e- cigarettes, attitudes towards e- cigarettes, beliefs 
about the harms of e- cigarettes particularly in compar-
ison to tobacco cigarettes and automatic motivation (how 
comfortable they feel giving smoking cessation advice 
in general and in giving specific advice on e- cigarettes 
to patients). A full copy of the questionnaire is available 
electronically from the authors.
Sample
The survey was distributed electronically by M3, the 
research arm of  doctors. net. uk, a leading market research 
consultancy specialising in high- quality online research 
using pre- recruited panels of medical professionals. All 
clinicians who are registered with  doctors. net. uk have 
to provide their clinical registration number during the 
registration process. M3 have 7781 GPs, 436 oncologists, 
708 surgeons, 221 cancer nurse specialists (CNSs) and 
315 practice nurses on their research panels. Sampling 
was restricted to currently practising clinicians, was strati-
fied by NHS region, and was conducted on a ‘first come, 
first served’ basis; the target number of responses was 
100 for each of the clinician types. When the quota of 
responses from each type of clinician or from each UK 
NHS region was reached, the survey was closed for that 
clinician group or region.
The survey was completed between November 2018 and 
February 2019. A small financial incentive was offered. 
Participants confirmed they had read the participant 
information and consented to take part via email before 
the survey link was sent.
Analyses
Anonymised electronic responses were imported into 
SPSS (V.25) for analysis. Frequencies and proportions 
were used to summarise questionnaire responses. Results 
are reported using the COM- B model: physical and 
psychological capability; physical and social opportunity; 
and automatic and reflective motivation.
Means and SD for each measure for the whole sample 
were calculated and then compared by clinician occupa-
tion. One- way analysis of variance was used to compare 
means for the other measures. Multiple comparisons 
were taken into account using a Bonferroni correc-
tion. Student- Newman- Keuls post hoc tests were used to 
examine differences reported.
Χ2 tests were used to compare the clinicians on categor-
ical measures. Binomial logistic regression models were 
used to predict the likelihood of recommending e- cig-
arettes to cancer patients. The dependent variable was 
dichotomised by always/nearly always/often recommend 
e- cigarettes (Q5_3) vs sometimes/infrequently/never.
Patient and public involvement
Cancer service users and vapour representatives were 
involved in the proposal development, questionnaire 
development and dissemination of the results of this 
study. One vapour representative was involved in the write 
up and is an author on the paper.
RESULTS
Characteristics of respondents
The online survey was completed by 506 clinicians: 103 
GPs, 102 oncologists, 100 cancer surgeons, 102 practice 
nurses and 99 CNSs. One CNS was excluded because they 
were a CNS for children. Table 1 describes the clinicians’ 
characteristics.
Reported behaviour
Twenty- nine precent n=147) of clinicians would not 
recommend e- cigarettes to patients with cancer who 
smoke. Just over half (51%, n=258) would recommend 
e- cigarettes as an interim measure, to help patients stop 
smoking completely, while 20% (n=101) would recom-
mend e cigarettes as a partial replacement for smoking 
tobacco.
Psychological capability
Most clinicians (78%, n=394) knew the smoking status 
of their patients with cancer, and routinely recorded 
their smoking status (73%, n=368). Sixty- seven per cent 
(n=339) reported that they routinely recommended 
patients stop smoking, or cut down (52%, n=263). Twenty- 
nine per cent (n=147) referred patients to the NHS stop 
smoking services, 14% (n=71) recommended nicotine 
replacement therapy, 9% (n=46) recommended digital 
smoking cessation tools and 5% (n=25) prescribed medi-
cation (varenicline or bupropion).
Many clinicians felt they had insufficient knowledge 
(57%, n=286) and training (73%, n=370) to provide 
advice about e- cigarettes to patients and a further 36% 
(n=182) indicated that they did not know the efficacy of 
e- cigarettes with regard to smoking cessation.
Clinicians derived information about e- cigarettes 
from several sources. Overall, only 9.5% (n=48) of clini-
cians knew whether their organisation had guidance 
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concerning advice to patients on e- cigarette use. Most 
clinicians had sought information about e- cigarettes 
from government/health agencies (55%), but also from 
professional associations (37%), healthcare colleagues 
(29%), news/media/advertising (24%), scientific liter-
ature (23%), professional development/training (22%) 
and charities (18%). Nineteen per cent of clinicians had 
never sought information about e- cigarettes. One- quarter 
of respondents (25%, n=124) were uncertain whether 
e- cigarettes were less harmful than smoking tobacco, while 
10% (n=52) thought e- cigarettes were equally harmful or 
more harmful than smoking tobacco. Eighteen per cent 
(n=93) considered using e- cigarettes to be more harmful 
than regular nicotine replacement therapies (eg, gum, 
nasal spray, patches) and 54% (n=273) were uncertain.
Table 1 Clinician characteristics
Demographics All participants % (n=506) Primary care % (n=205) Secondary care % (n=301)
Gender
  Male 41.1 35.1 45.2
  Female 57.5 63.9 53.2
Prefer not to say 1.4 1.0 1.7
  Years of professional experience 1995 (1968–2009) 1994 1996
Role
  General practitioner 20.4 40.5
  Practice nurse 20.2
  Cancer surgeon 19.8 59.5
  Oncologist 20.2
  Cancer nurse specialist 19.6
NHS region
  London 15.8 12.2 18.3
  South of England 21.1 21.5 20.9
  Midlands and East SEA 25.5 25.4 25.6
  North of England 20.6 22.9 18.9
  Scotland 12.1 13.7 11.0
  Wales 2.2 2.4 2.0
  Northern Ireland 2.8 2.0 3.3
Main cancer group they care for
  All 37.0 76.1 10.3
  Breast 24.1 12.2 32.2
  Prostate 19.4 13.7 23.3
  Lung/mesothelioma 18.0 11.7 22.3
  Bowel 11.9 5.4 16.3
  Kidney 11.9 0.5 19.6
  Bladder 11.3 0.5 18.6
  Other cancer groups <10 <5 <15
Smoking status of clinicians
  Smoke tobacco cigarettes 2.0 1.5 2.3
  Use e- cigarettes** 1.2 1.5 1.0
  Ex- smoker 21.3 22.9 20.3
  Never smoker 72.3 72.2 72.4
  Other 1.4 1.5 1.3
  Prefer not to say 3.6 2.4 4.3
NHS, National Health Service.
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Physical opportunity
The majority of clinicians (56%, n=285) said that e- cig-
arette use was prohibited in all areas at their main place 
of work. Twenty- three per cent (n=119) reported that 
the use of e- cigarettes was permitted, with 24% (n=29) 
reporting use in designated smoking areas only. Overall, 
51% (n=258) agreed that time constrained their ability to 
talk about e- cigarettes with patients.
Social opportunity
The nature of the relationships between clinicians and 
patients with cancer were important in whether and 
how smoking cessation was discussed. Fifty- five per cent 
(n=278) of clinicians reported that having a good rela-
tionship would make them more likely to speak to their 
patient about stopping or cutting down, while 45% 
(n=228) reported that having a poor relationship would 
make them less likely to discuss smoking cessation. Many 
clinicians (42% n=212) felt uncomfortable when asked by 
patients for an opinion on e- cigarettes. The large majority, 
82%, had been asked about e- cigarettes by patients in the 
past year (2017/18), up from 21% in 2016/2017.
Thirty- eight per cent (n=192) said that most of their 
colleagues would feel uncomfortable recommending 
e- cigarettes to patients with cancer, and 37% (n=187) were 
unsure whether clinicians should discourage patients 
with cancer from using e- cigarettes.
Automatic motivation
Subconscious biases towards e- cigarettes were influenced 
by clinicians’ beliefs around the effectiveness of and 
evidence on e- cigarettes, as reported in the psychological 
capability section above.
Clinicians reported that their decisions to speak with 
patients with cancer about smoking cessation were influ-
enced by their perceptions of the patient. Clinicians 
reported that they were more likely to discuss smoking 
cessation if they judged the person was motivated to quit 
(69%, n=349), or was coping well (67%, n=339).
Reflective motivation
Reflective motivation related to the clinicians’ perceived 
role in smoking cessation and national and organisa-
tional policy on e- cigarettes. Two- thirds (65%, n=327) of 
clinicians agreed that they should play a greater role in 
helping cancer patients stop smoking. Clinicians were 
divided over whether e- cigarettes should be licensed and 
available on prescription for patients with cancer, with 
39% (n=199) respondents disagreeing, and 32% (n=162) 
saying they should be available on prescription. Further-
more, 30% (n=150) of clinicians felt that public health 
campaigns, such as Stoptober should not endorse using 
e- cigarettes as a way to give up smoking tobacco, while 
29% (n=149) thought e- cigarettes should be endorsed in 
campaigns.
Differences in e-cigarettes practice between clinicians
GPs and practice nurses were significantly more likely 
to say that they recommended e- cigarettes to cancer 
patients than the other clinicians included in the study 
(see table 2).
GPs and practice nurses also rated their knowledge 
about e- cigarettes higher than did specialist cancer care 
clinicians, and were also more likely to report having 
sufficient time to discuss smoking with patients and rated 
their role in helping patients cut down smoking as more 
important.
Practice nurses engaged in significantly more 
behaviours (eg, ascertaining smoking status, advising 
patients, supporting e- cigarette use in patients) related to 
smoking cessation with patients than all the other groups. 
GPs engaged in significantly more behaviours than the 
other clinicians, but fewer than practice nurses. Practice 
nurses were significantly more likely to believe in the 
effectiveness of e- cigarettes in helping cancer patients 
stop smoking compared with other clinicians.
Logistic regression model
Table 3 presents a logistic regression model including all 
COM- B factors and controlling for clinician type. In this 
model, not recommending e- cigarettes is associated with 
a lack of knowledge regarding smoking cessation (OR 
1.56, 95% CI 1.01 to 2.44) and e- cigarettes (OR 1.64, 95% 
CI 1.06 to 2.55). Additionally, greater engagement with 
patients regarding smoking cessation (OR 2.12, 95% CI 
1.12 to 4.03), belief in the effectiveness of e- cigarettes (OR 
2.36, 95% CI 1.61 to 3.47), belief in sufficient evidence on 
e- cigarettes (OR 2.08, 95% CI 1.10 to 4.00) and the social 
opportunity factor of how comfortable they felt discussing 
e- cigarettes with patients (OR 1.57, 95% CI 1.04 to 2.36) 
all significantly predicted recommending e- cigarettes to 
cancer patients. Specifically, those who reported higher 
levels of engagement around smoking cessation, and 
those who were comfortable discussing e- cigarettes were 
more likely to recommend them. However, those who felt 
the evidence base was lacking were less likely to recom-
mend them.
DISCUSSION
The findings from this study suggest relatively low levels 
of clinician support around recommending e- cigarettes 
to patients with cancer. Despite a growing evidence base 
to support use and popularity of e- cigarettes as a smoking 
cessation aid in the UK, nearly one- third of clinicians do 
not recommend e- cigarettes to patients with cancer who 
smoke. Not recommending e- cigarettes is associated with 
a lack of knowledge regarding smoking cessation and 
e- cigarettes, lack of engagement in smoking cessation 
practices with patients that smoke, low belief in effective-
ness of e- cigarettes, low belief in evidence around e- ciga-
rettes, and not feeling comfortable discussing e- cigarettes 
with their patients.
In line with the results of this study, a survey of 124 
members of The British Thoracic Oncology Group in 
April 2015 showed that 93% of clinicians agreed that they 
needed more information and guidance on e- cigarettes 
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to advise patients. Clinicians lacked confidence to advise 
patients with lung cancer to use e- cigarettes.47 Our find-
ings indicate that, 3 years after this study, clinicians 
continue to lack knowledge and confidence in recom-
mending e- cigarettes to patients with cancer despite a 
UK public health policy to support e- cigarettes. Clini-
cians from various specialties have reported a need for 
training and local guidance around e- cigarettes in line 
with the national public health policy.43 50 Interventions 
are needed to target the reported behavioural factors 
associated with clinicians’ reluctance to recommend 
e- cigarettes.
This study highlights that the COM- B components 
of psychological capability, social opportunity and 
automatic and reflective motivation were all associated 
with clinicians’ beliefs and behaviours around recom-
mending e- cigarettes. Improving knowledge through 
accessible training on e- cigarettes alongside local 
adoption of public health policies around e- cigarettes 
throughout the NHS may support clinicians to feel more 
confident and comfortable in recommending them to 
patients. The National Institute for Health and Care 
Excellence in the UK advise that clinicians have an 
informed discussion with patients on use of e- cigarettes 
to stop smoking.51
A recent study reports that practitioners suggested the 
development of decision aids around e- cigarettes, such as 
a leaflet, booklet or online resource to use during consul-
tations with patients.52 This would aid a more ‘neutral’ 
decision around use of e- cigarettes and potentially 
improve confidence around discussions on e- cigarettes.53 
Furthermore, engagement from local clinical commis-
sioning groups and clinical leads alongside accessible 
training may support clinicians in providing advice on 
e- cigarettes to patients with cancer.
To date, there is no medicinally licensed EC in the UK, 
or anywhere else in the world, which is possibly presenting 
challenges for clinicians wishing to demonstrate e- ciga-
rettes or recommend for inpatient use. In this study, clini-
cians were divided over this decision, with two- fifths of 
clinicians not supportive, and nearly one- third supportive 
of licensing e- cigarettes for medicinal uses. Clinicians 
Table 2 COM- B measures by HP—mean and SD
Total
General 
practitioner
Practice 
nurse
Cancer 
surgeon Oncologist
Cancer nurse 
specialist
Test statistic, P 
value
No of participants 506 103 102 100 102 99
Recommend e- cigarettes 
always/often, N (%)
97 (19.2) 24 (23.3) 36 (35.3) 9 (9) 16 (15.7) 12 (12.1) χ2=28.90, <0.001
Capability
  Know status 4.72 (0.59) 4.75 (0.48) 4.78 (0.46) 4.81 (0.46) 4.75 (0.60) 4.52 (0.81) F=4.17, 0.002*
  General smoking 
knowledge
3.40 (1.03) 3.80 (0.86) 3.75 (1.08) 3.10 (1.00) 3.17 (1.03) 3.19 (0.95) F=12.09, <0.001*
  E- cig knowledge 2.34 (.99) 2.40 (0.89) 2.45 (1.07) 2.21 (0.94) 2.54 (1.05) 2.11 (0.95) F=3.32, 0.011
Opportunity
  Time 2.60 (1.03) 2.46 (0.95) 2.87 (.94) 2.39 (1.00) 2.29 (1.06) 3.02 (1.00) F=10.47, <0.001*
  Patient relationships 2.51 (.68) 2.45 (0.72) 2.52 (0.66) 2.59 (0.64) 2.49 (0.67) 2.52 (0.72) F=0.59, 0.668
  Social norms 3.00 (0.72) 2.98 (0.86) 3.18 (0.75) 2.85 (0.66) 3.08 (0.65) 2.91 (0.64) F=3.36, 0.010
Motivation
  Engagement with 
patients who smoke
2.77 (0.61) 2.90 (0.55) 3.21 (0.55) 2.60 (0.54) 2.55 (0.58) 2.59 (0.55) F=26.13, <0.001*
  Effectiveness in helping 
cancer pts
2.83 (1.50) 2.86 (1.48) 3.39 (1.43) 2.49 (1.54) 2.81 (1.45) 2.57 (1.44) F=5.89, <0.001*
  Importance of HP role 4.35 (0.76) 4.48 (0.62) 4.60 (0.60) 4.33 (0.83) 4.20 (0.81) 4.15 (0.84) F=6.40, <0.001*
  Lack of evidence N (%) 242 (47.8) 57 (55.3) 51 (50) 44 (44) 41 (40.2) 50 (50.5) χ2=5.60, 0.231
  Attitudes 3.22 (0.61) 3.23 (0.64) 3.39 (0.62) 3.08 (0.61) 3.26 (0.53) 3.13 (0.59) F=0.4.04, 0.003
  Harm 3.16 (0.68) 3.25 (0.63) 3.15 (0.67) 3.18 (0.66) 3.22 (0.71) 3.01 (0.71) F=1.32, 0.263
  Better than smoking 3.86 (0.96) 4.00 (1.00) 3.84 (1.00) 3.82 (.81) 4.07 (0.86) 3.56 (1.05) F=4.39, 0.002*
  Comfortable discussing 
smoking in general
4.40 (0.76) 4.45 (0.75) 4.44 (0.71) 4.49 (0.72) 4.39 (0.81) 4.24 (0.80) F=1.59, 0.175
  Comfortable discussing 
e- cigs
2.91 (1.16) 3.09 (1.13) 3.04 (1.23) 2.65 (1.17) 3.00 (1.11) 2.76 (1.12) F=2.79, 0.026
*Significant for F tests when multiple comparisons taken into consideration, accepted p value corrected to 0.003.
COM- B, capability, opportunity and motivation to perform a behaviour.
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may be more comfortable recommending e- cigarettes if 
they were available on prescription.
Debate is also needed on how e- cigarettes could be 
integrated into smoking cessation practices delivered by 
clinicians to patients with cancer. Smoking cessation prac-
tices are already well developed in other disease groups 
such as coronary heart disease.54 It is, therefore, timely 
to examine the role of a smoking cessation service within 
the cancer pathway, including the role of e- cigarettes can 
play in helping cancer patients to quit smoking long term 
after a diagnosis.55 While attendance at a cancer clinic 
provides an opportunity for clinicians to provide smoking 
cessation support to those who smoke, this is not currently 
routinely offered. Patients with cancer have highlighted 
the need for smoking cessation support, and have 
reported difficulty in attending external smoking cessa-
tions services in addition to all their other clinic appoint-
ments.12 Smoking cessation advice has historically been 
the role of primary care or community smoking cessation 
services, and this is reflected in the greater knowledge, 
confidence and more positive attitude towards e- ciga-
rettes among practice nurses and GPs than among cancer 
specialists reported in this study. However, lack of funding 
has seen a decline in the smoking cessation services and 
alternatives are needed. Clinicians worry that discussing 
smoking may damage the relationship with the patient, 
which is essential for the often onerous treatment needed 
for cancer.53 Clinicians also seem to believe that patients 
cannot stop smoking.56
Strengths and limitations
To our knowledge, this study is the first to examine a broad 
range of clinicians’ behaviours and beliefs around the use 
of e- cigarettes in patients across different cancer groups. 
The COM- B model has previously been used to develop 
smoking cessation interventions.57 In this study, it has 
enabled the identification of factors, which could be used 
to improve clinicians’ recommendation of e- cigarettes.
Table 3 Results of full binary logistic regression model exploring all factors relating to capability, opportunity and motivation 
to recommend e- cigarettes to patients with cancer
95% CI for OR
B Wald (df=1) P value Lower OR Upper
Capability
  Know status 0.758 3.320 0.068 0.944 2.134 4.821
  General smoking knowledge −0.440 3.866 0.049 1.010 1.563 2.439
  E- cig knowledge 0.495 4.878 0.027 1.057 1.641 2.546
Opportunity
  Time 0.083 0.237 0.626 0.778 1.087 1.517
  Patient relationships −0.092 0.128 0.720 0.551 0.912 1.510
  Social norms −0.047 0.028 0.867 0.549 0.954 1.658
Motivation
  Engagement with patients who smoke 0.752 5.308 0.021 1.119 2.122 4.025
  Effectiveness in helping cancer pts 0.858 19.09 0.000 1.605 2.359 3.466
  Importance of HP role 0.259 0.834 0.361 0.743 1.295 2.257
  Sufficient evidence −0.745 4.963 0.026 1.099 2.083 4.000
  Attitudes 0.370 1.038 0.308 0.711 1.447 2.947
  Harm 0.023 0.006 0.941 0.556 1.023 1.885
  Better than smoking −0.009 0.001 0.972 0.593 0.991 1.655
  Comfortable discussing smoking in general −0.402 2.180 0.140 0.392 0.669 1.141
  Comfortable discussing e- cigs 0.448 4.594 0.032 1.039 1.565 2.356
Health professional (HP) type
  5.385 0.250
  GP 0.276 0.256 0.613 0.453 1.318 3.839
  Practice nurse 0.281 0.294 0.588 0.479 1.324 3.659
  Cancer surgeon −0.805 1.791 0.181 0.138 0.447 1.453
  Oncologist −0.391 0.514 0.473 0.232 0.676 1.971
  Constant −11.416 20.331 0.000 0.000
Reference categories—for HP type=cancer nurse specialist, for sufficient evidence=yes, 2.08, 95% CI 1.10 to 4.00.
GP, general practitioner.
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The recruitment procedure for this survey used an 
existing network of electronically active clinicians from 
the research arm of  doctors. net. com. This method 
has the advantage of speed and guaranteed response 
which is beneficial considering that surveys with busy 
clinicians have commonly suffered from poor response 
rates. However, this sample may not be representative of 
the population of clinicians in the UK. Quota sampling 
ensured diversity in our sample, which included clini-
cians who worked with patients who had a wide range of 
cancer diagnoses, and not just those with cancers directly 
associated with smoking. However, in quota sampling, the 
sample has not been chosen using random selection
The potential for response bias should be considered; 
for example, those with a greater interest in smoking 
cessation for cancer patients may have been more likely 
to respond, and the incentive may have encouraged 
participation, whereas clinicians who are smokers may 
have been under- represented. In addition, findings rely 
on self- report.
CONCLUSIONS
Despite the evidence that e- cigarettes help smokers quit 
smoking, and the positive public health stance towards 
e- cigarettes in the UK, clinicians remain cautious about 
recommending e- cigarettes to cancer survivors who 
continue to smoke. Clinicians require training and 
support on how to integrate e cigarettes in smoking cessa-
tion advice for patients with cancer and adoption of the 
UK evidence based guidance at regional and local level 
is needed.
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